Los Angeles, October 15, 2024 — Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide […]
Los Angeles, July 16, 2024 — Trethera Corporation, a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism
Los Angeles, September 25, 2023 — Trethera Corporation, a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism
Los Angeles, September 5, 2023 — Trethera Corporation, a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism
Los Angeles, June 28, 2023 — Trethera Corporation, a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism
Los Angeles, June 27, 2023 — Trethera Corporation, a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism
Los Angeles, May 30, 2023 — Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide
Los Angeles, March 15, 2023 — Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide
Los Angeles, February 15, 2023 — Trethera Corporation (“Trethera”), a clinical-stage biopharmaceutical company committed to developing novel drugs targeting nucleotide
Los Angeles, January 24, 2023 — Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting
Your feedback is very important to us. We will get back to you within 48 hours.
13547 Ventura Boulevard,
Suite 363
Sherman Oaks, CA 91423